Results 141 to 150 of about 2,434,139 (259)

The TOP‐GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non‐Asian Population

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In this randomized, double‐blind trial in Mexican adults with erosive oesophagitis, tegoprazan did not significantly improve the primary 4‐week ITT healing endpoint versus pantoprazole (88.9% vs. 79.4%; p = 0.33), but produced faster symptom improvement. Encouraging per‐protocol and severe‐oesophagitis findings warrant confirmation.
José M. Remes‐Troche   +9 more
wiley   +1 more source

Early life exposures as risk factors for non-esophageal eosinophilic gastrointestinal diseases. [PDF]

open access: yesClin Res Hepatol Gastroenterol, 2023
Jensen ET   +9 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Fibrillar‐Type Dermatitis Herpetiformis: An Underrecognized Variant That Is Rarely Associated With Celiac Disease and Lacking Epidermal Transglutaminase Deposition: A Report of Two Cases

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Dermatitis herpetiformis (DH) is a rare, intensely pruritic cutaneous manifestation of celiac disease (CD), typically presenting with excoriated papulovesicular lesions on extensor surfaces. DH is associated with IgA autoantibodies against epidermal transglutaminase (eTG), which form granular immune deposits in the papillary dermis and induce ...
Jeffrey Damman   +5 more
wiley   +1 more source

Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting. [PDF]

open access: yesJ Allergy Clin Immunol, 2023
Chehade M   +30 more
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo   +6 more
wiley   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Behind the scenes: Primary immunodeficiencies in pediatric eosinophilic gastrointestinal diseases. [PDF]

open access: yesPediatr Allergy Immunol
Baskin K   +10 more
europepmc   +1 more source

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

open access: yes
Allergy, EarlyView.
Guillaume Lefèvre   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy